FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809107816> ?p ?o ?g. }

• W2809107816 abstract "There is limited comparative evidence for the CV safety and hypoglycemia risk of basal insulins in older patients with T2D. This secondary analysis from DEVOTE investigated the CV safety and severe hypoglycemia risk of insulin degludec (degludec) vs. insulin glargine 100 units/mL (glargine U100) in older patients (65-74 and ?75 years age groups). Data from DEVOTE (a treat-to-target, randomized, double-blind trial evaluating 7637 patients with T2D over a median period of 2 years at high risk of CV events) were stratified by three age groups. At baseline, A1C, fasting plasma glucose and estimated glomerular filtration rates decreased with increasing age. Older patients had a higher risk of major adverse cardiovascular events (MACE), all-cause mortality and severe hypoglycemia, regardless of treatment. Treatment differences for MACE, all-cause mortality and severe hypoglycemia were similar across age groups (Figure), with no significant interactions between treatment and age group. Degludec was associated with a lower risk of severe hypoglycemia vs. glargine U100, regardless of age. This analysis supported the CV safety of degludec and demonstrated a lower risk of severe hypoglycemia vs. glargine U100 in older patients with T2D. Disclosure R.E. Pratley: Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eisai Inc., GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc., Pfizer Inc., Sanofi-Aventis, Takeda Development Center Americas, Inc. S.S. Emerson: Consultant; Self; Bayer AG, CTI BioPharma, Arena Pharmaceuticals, SFJ Pharmaceuticals Group, Genentech, Inc., GlaxoSmithKline plc., Janssen Research & Development, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Pharma, Allergan, AstraZeneca, Coherus Biosciences Inc, Emmaus Life Sciences Inc., Indivior, Sandoz, Seattle Genetics. Research Support; Self; National Heart, Lung, and Blood Institute. E. Franek: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Novo Nordisk A/S. Speaker's Bureau; Self; AstraZeneca, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co., Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Servier. M.P. Gilbert: Consultant; Self; Sanofi US, Novo Nordisk A/S. S.P. Marso: Consultant; Self; Abbott Vascular, Novo Nordisk A/S, University of Oxford, AstraZeneca, Bristol-Myers Squibb Company. Research Support; Self; Novo Nordisk A/S, The Medicines Company, Terumo Medical Corporation. D.K. McGuire: Consultant; Self; AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Novo Nordisk A/S. Research Support; Self; AstraZeneca, Sanofi-Aventis, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Lexicon Pharmaceuticals, Inc., Eisai Inc., GlaxoSmithKline plc., Esperion Therapeutics. T.R. Pieber: Consultant; Self; Arecor, AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Employee; Self; CBmed. Research Support; Self; Novo Nordisk A/S, AstraZeneca. N.R. Poulter: Advisory Panel; Self; AstraZeneca, Novo Nordisk A/S, Amgen Inc.. Research Support; Self; Servier. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk A/S, Amgen Inc., Servier. Other Relationship; Self; International Society of Hypertension. C.T. Hansen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. M.V. Hansen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. T. Mark: Employee; Self; Novo Nordisk A/S. Employee; Spouse/Partner; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. A.C. Moses: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. B. Zinman: Consultant; Self; Novo Nordisk A/S, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Sanofi, Merck & Co., Inc., Abbott." @default.
• W2809107816 created "2018-06-29" @default.
• W2809107816 creator A5010362836 @default.
• W2809107816 creator A5011985941 @default.
• W2809107816 creator A5026176656 @default.
• W2809107816 creator A5030909625 @default.
• W2809107816 creator A5032817714 @default.
• W2809107816 creator A5035502539 @default.
• W2809107816 creator A5037724247 @default.
• W2809107816 creator A5040628721 @default.
• W2809107816 creator A5058457879 @default.
• W2809107816 creator A5059098934 @default.
• W2809107816 creator A5071945904 @default.
• W2809107816 creator A5072011562 @default.
• W2809107816 creator A5090993994 @default.
• W2809107816 date "2018-07-01" @default.
• W2809107816 modified "2023-09-26" @default.
• W2809107816 title "Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (=65 Years) with Type 2 Diabetes (T2D)—Observations from DEVOTE" @default.
• W2809107816 doi "https://doi.org/10.2337/db18-108-or" @default.
• W2809107816 hasPublicationYear "2018" @default.
• W2809107816 type Work @default.
• W2809107816 sameAs 2809107816 @default.
• W2809107816 citedByCount "1" @default.
• W2809107816 countsByYear W28091078162018 @default.
• W2809107816 crossrefType "journal-article" @default.
• W2809107816 hasAuthorship W2809107816A5010362836 @default.
• W2809107816 hasAuthorship W2809107816A5011985941 @default.
• W2809107816 hasAuthorship W2809107816A5026176656 @default.
• W2809107816 hasAuthorship W2809107816A5030909625 @default.
• W2809107816 hasAuthorship W2809107816A5032817714 @default.
• W2809107816 hasAuthorship W2809107816A5035502539 @default.
• W2809107816 hasAuthorship W2809107816A5037724247 @default.
• W2809107816 hasAuthorship W2809107816A5040628721 @default.
• W2809107816 hasAuthorship W2809107816A5058457879 @default.
• W2809107816 hasAuthorship W2809107816A5059098934 @default.
• W2809107816 hasAuthorship W2809107816A5071945904 @default.
• W2809107816 hasAuthorship W2809107816A5072011562 @default.
• W2809107816 hasAuthorship W2809107816A5090993994 @default.
• W2809107816 hasConcept C126322002 @default.
• W2809107816 hasConcept C134018914 @default.
• W2809107816 hasConcept C187212893 @default.
• W2809107816 hasConcept C2775927303 @default.
• W2809107816 hasConcept C2777180221 @default.
• W2809107816 hasConcept C2779306644 @default.
• W2809107816 hasConcept C2779920387 @default.
• W2809107816 hasConcept C2780668416 @default.
• W2809107816 hasConcept C555293320 @default.
• W2809107816 hasConcept C71924100 @default.
• W2809107816 hasConceptScore W2809107816C126322002 @default.
• W2809107816 hasConceptScore W2809107816C134018914 @default.
• W2809107816 hasConceptScore W2809107816C187212893 @default.
• W2809107816 hasConceptScore W2809107816C2775927303 @default.
• W2809107816 hasConceptScore W2809107816C2777180221 @default.
• W2809107816 hasConceptScore W2809107816C2779306644 @default.
• W2809107816 hasConceptScore W2809107816C2779920387 @default.
• W2809107816 hasConceptScore W2809107816C2780668416 @default.
• W2809107816 hasConceptScore W2809107816C555293320 @default.
• W2809107816 hasConceptScore W2809107816C71924100 @default.
• W2809107816 hasIssue "Supplement_1" @default.
• W2809107816 hasLocation W28091078161 @default.
• W2809107816 hasOpenAccess W2809107816 @default.
• W2809107816 hasPrimaryLocation W28091078161 @default.
• W2809107816 hasRelatedWork W2017030704 @default.
• W2809107816 hasRelatedWork W2052274943 @default.
• W2809107816 hasRelatedWork W2071740101 @default.
• W2809107816 hasRelatedWork W2086873292 @default.
• W2809107816 hasRelatedWork W2103017735 @default.
• W2809107816 hasRelatedWork W2329524306 @default.
• W2809107816 hasRelatedWork W2580031818 @default.
• W2809107816 hasRelatedWork W2590876842 @default.
• W2809107816 hasRelatedWork W3197438476 @default.
• W2809107816 hasRelatedWork W4294903945 @default.
• W2809107816 hasVolume "67" @default.
• W2809107816 isParatext "false" @default.
• W2809107816 isRetracted "false" @default.
• W2809107816 magId "2809107816" @default.
• W2809107816 workType "article" @default.